<DOC>
	<DOCNO>NCT00834197</DOCNO>
	<brief_summary>This study compare relative bioavailability ( rate extent absorption ) 15 mg Mirtazapine ( Orally Disintegrating ) Tablets manufactured TEVA Pharmaceutical Industries , Ltd. ; distribute TEVA Pharmaceuticals USA 15 mg REMERON SolTabÂ® Orally Disintegrating Tablets manufacture Organon Inc. CIMA Labs Inc. follow single oral dose ( 1 x 15 mg ) healthy adult subject non-fasting condition .</brief_summary>
	<brief_title>15 mg Mirtazapine Orally Disintegrating Tablets , Non-Fasting</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<criteria>Screening Demographics : All subject select study healthy men woman 18 year age old time dose . The subject 's body mass index ( BMI ) less equal 30 . Screening Procedures : Each subject complete screening process within 28 day prior Period I dose . Consent document screen evaluation HIV antibody determination review , discuss , sign potential participant fill implementation screening procedure . Screening include general observation , physical examination , demographic , medical medication history , electrocardiogram , sit blood pressure heart rate , respiratory rate temperature . The physical examination include , may limit , evaluation cardiovascular , gastrointestinal , respiratory central nervous system . The screen clinical laboratory include : Hematology : hematocrit , hemoglobin , WBC count differential , RBC count , platelet count ; Clinical Chemistry : serum creatinine , BUN , glucose , AST ( GOT ) , ALT ( GPT ) , albumin , total bilirubin , total protein , alkaline phosphatase ; HIV antibody , hepatitis B surface antigen , hepatitis C antibody screen ; Urinalysis : dipstick ; full microscopic examination dipstick positive ; Urine Drug Screen : ethyl alcohol , amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine metabolite , opiates phencyclidine . Serum Pregnancy Screen ( female subject ) If female : childbearing potential , practice acceptable barrier method birth control duration study judge investigator ( ) , condom , sponge , foam , jelly , diaphragm , intrauterine device ( IUD ) , abstinence ; postmenopausal least 1 year ; surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) . Subjects recent history drug alcohol addiction abuse . Subjects presence clinically significant disorder involve cardiovascular , respiratory , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease ( determined clinical investigator ) . Subjects whose clinical laboratory test value outside accept reference range confirm reexamination deem clinically significant . Subjects demonstrate positive hepatitis B surface antigen screen , hepatitis C antibody screen , reactive HIV antibody screen . Subjects demonstrate positive pregnancy screen . Subjects currently breastfeed . Subjects history clinically significant allergy include drug allergy . Subjects history allergic response ( ) mirtazapine relate drug . Subjects clinically significant illness 4 week prior Period I dose ( determined clinical investigator ) . Subjects currently use use tobacco product within 90 day Period I dose . Subjects take drug know induce inhibit hepatic drug metabolism 28 day prior Period I dose . Subjects report donate great 150 mL blood within 28 day prior Period I dose . All subject advise donate blood four week complete study . Subjects donate plasma ( e.g . plasmapheresis ) within 14 day prior Period I dose . All subject advise donate plasma four week complete study . Subjects report receive investigational drug within 28 day prior Period I dose . Subjects report take systemic prescription medication 14 day prior Period I dose . Subjects report intolerance direct venipuncture . Subjects report consume abnormal diet 28 day prior Period I dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>